Tuesday November 24 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Pharmaleads

Pharmaleads is a research company focussed on the custom design of substrates and inhibitors of zinc metallopeptidases and proteases.

Pharmaleads has already developed molecules for ECE, NEP, ACE, APN, APA,...



Pharmaleads has designed a substrate that detect botulinum toxin A and B at low concentration. It is available for pharmaceutical industries as a substrate or through technology licencing agreement. A product called EzyBot for the field detection of botulism is marketed by Pharmaleads for biodefense applications (bioterrorism).


Contact Details:
Universite Paris 7 - Bichat 16 rue Henri Huchard BP 416
PARIS
75870 cedex 18
France
Tel:
Fax:
Email:info@pharmaleads.com
WWW:

www.pharmaleads.com




Recent Publications by Pharmaleads:

Detection and quantification of botulinum neurotoxin type a by a novel rapid in vitro fluorimetric assay.
Botulinum neurotoxin type A (BoNT/A), the most poisonous substance known...
12th August, 2009
Pharmaleads, Paris BioPark, France. Appl Environ Microbiol. 2009 Jul;75(13):4382-90. Epub 2009 May 8.
DOI Direct Link
Structure of aminopeptidase N from Escherichia coli complexed with the transition-state analogue aminophosphinic inhibitor PL250.
Aminopeptidase N (APN; EC 3.4.11.2) purified from Escherichia coli has...
23rd July, 2009
Pharmaleads, France. Acta Crystallogr D Biol Crystallogr. 2009 Aug;65(Pt 8):814-22. Epub 2009
DOI Direct Link

Press Releases on Pharmaleads:

BioPortfolio Logo
Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions 17th November, 2008 The Debiopharm Group
LAUSANNE, Switzerland and PARIS, November 17 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and
Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2nd October, 2008
PARIS, October 2 /PRNewswire/ -- Pharmaleads has obtained from the French Medicine Agency (AFSSAPS) the authorization to perform a single ascending dose Phase I study with PL37, its lead compound for

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 315 times since April 2007, the link to the organisation's website has been followed 56 times

Recent Search Terms used to find this page: Pharmaleads | .

Search for more companies in PARIS

Search for more companies in



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Pharmaleads

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.